Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.

Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F.

Eur J Cancer. 2019 Jan;107:164-174. doi: 10.1016/j.ejca.2018.11.016. Epub 2018 Dec 19.

PMID:
30579113
2.

The right chance for temozolomide in metastatic colorectal cancer?

Sartore-Bianchi A, Siena S.

Ann Oncol. 2018 Aug 1;29(8):1618-1619. doi: 10.1093/annonc/mdy223. No abstract available.

3.

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.

Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F.

Ann Oncol. 2018 Aug 1;29(8):1800-1806. doi: 10.1093/annonc/mdy197.

PMID:
29860358
4.

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.

Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR.

Cancer. 2018 Jun 1;124(11):2337-2346. doi: 10.1002/cncr.31309. Epub 2018 Mar 26.

5.

Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer.

Tóth C, Sükösd F, Valicsek E, Herpel E, Schirmacher P, Tiszlavicz L.

Oncol Lett. 2018 Mar;15(3):3586-3593. doi: 10.3892/ol.2018.7756. Epub 2018 Jan 9.

6.

Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients.

Shalaby SM, El-Shal AS, Abdelaziz LA, Abd-Elbary E, Khairy MM.

Gene. 2018 Feb 20;644:66-73. doi: 10.1016/j.gene.2017.10.056. Epub 2017 Nov 17.

PMID:
29080834
7.

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.

Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G, Schiavetto I, Bencardino K, Funaioli C, Ricotta R, Cipani T, Schirru M, Gambi V, Palmeri L, Carlo-Stella G, Rusconi F, Di Bella S, Burrafato G, Cassingena A, Valtorta E, Lauricella C, Pazzi F, Gambaro A, Ghezzi S, Marrapese G, Tarenzi E, Veronese S, Truini M, Vanzulli A, Siena S.

Target Oncol. 2017 Aug;12(4):525-533. doi: 10.1007/s11523-017-0505-6.

8.

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.

Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, Gori S, Tonini G, Barone C.

Br J Cancer. 2017 May 9;116(10):1279-1286. doi: 10.1038/bjc.2017.109. Epub 2017 Apr 20.

9.

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.

Borazanci E, Millis SZ, Kimbrough J, Doll N, Von Hoff D, Ramanathan RK.

J Gastrointest Oncol. 2017 Feb;8(1):164-172. doi: 10.21037/jgo.2017.01.14.

10.

Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.

Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomatà C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, De Braud F, Di Nicolantonio F, Barault L, Siena S.

Eur J Cancer. 2017 Jan;71:43-50. doi: 10.1016/j.ejca.2016.10.032. Epub 2016 Dec 18.

11.

How the lab is changing our view of colorectal cancer.

Cremolini C, Pietrantonio F.

Tumori. 2016 Dec 1;102(6):541-547. doi: 10.5301/tj.5000551. Epub 2016 Sep 20. Review.

PMID:
27647226
12.

MGMT in colorectal cancer: a promising component of personalized treatment.

Zhang L, Zeng J, Zeng Z, Wang F, Wang D, Chen C, Li C, An X, Xu R, Huang P, Ba Y, Li Y.

Tumour Biol. 2016 Aug;37(8):11443-56. doi: 10.1007/s13277-016-5014-1. Epub 2016 Mar 22.

PMID:
27006309
13.

Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.

Amatu A, Barault L, Moutinho C, Cassingena A, Bencardino K, Ghezzi S, Palmeri L, Bonazzina E, Tosi F, Ricotta R, Cipani T, Crivori P, Gatto R, Chirico G, Marrapese G, Truini M, Bardelli A, Esteller M, Di Nicolantonio F, Sartore-Bianchi A, Siena S.

Ann Oncol. 2016 Jun;27(6):1062-7. doi: 10.1093/annonc/mdw071. Epub 2016 Feb 24.

PMID:
26916096
14.

Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond.

Fornaro L, Vivaldi C, Caparello C, Musettini G, Baldini E, Masi G, Falcone A.

Front Biosci (Elite Ed). 2016 Jan 1;8:170-80. Review.

PMID:
26709653
15.

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S.

Cancer Biol Ther. 2015;16(12):1726-37. doi: 10.1080/15384047.2015.1113356.

16.

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Rudà R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F.

Ann Oncol. 2015 Sep;26(9):1994-9. doi: 10.1093/annonc/mdv272. Epub 2015 Jun 25.

17.

MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors.

De Maglio G, Casagrande M, Guardascione M, Fontanella C, Lutrino SE, Rihawi K, Pisa FE, Tuniz F, Fasola G, Pizzolitto S, Aprile G.

Future Oncol. 2015;11(8):1201-9. doi: 10.2217/fon.15.2.

PMID:
25832877
18.

Role of MGMT as biomarker in colorectal cancer.

Inno A, Fanetti G, Di Bartolomeo M, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, de Braud F, Bossi I, Pietrantonio F.

World J Clin Cases. 2014 Dec 16;2(12):835-9. doi: 10.12998/wjcc.v2.i12.835. Review.

19.

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

Pietrantonio F, Perrone F, de Braud F, Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M, Busico A, Gariboldi M, Festinese F, Tamborini E, Di Bartolomeo M.

Ann Oncol. 2014 Feb;25(2):404-8. doi: 10.1093/annonc/mdt547. Epub 2013 Dec 29.

PMID:
24379162
20.

Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population.

Sinha R, Hussain S, Mehrotra R, Kumar RS, Kumar K, Pande P, Doval DC, Basir SF, Bharadwaj M.

PLoS One. 2013;8(4):e60142. doi: 10.1371/journal.pone.0060142. Epub 2013 Apr 3.

Supplemental Content

Loading ...
Support Center